Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Triple Therapy CS-8635 in Hypertension
NCT01838850Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Apr 2013
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of olmesartan medoxomil + amlodipine + hydrochlorothiazide in essential hypertension (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: The changes of seated diastolic blood pressure at 8 weeks. Started Apr 2013; status: completed.
02
Drugs
olmesartan medoxomil + amlodipine + hydrochlorothiazide
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT01838850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01838850.